Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.

Authors :: Belley A
Lalonde-Séguin D
Arhin FF
Moeck G
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Sep 22; Vol. 61 (10). Date of Electronic Publication: 2017 Sep 22 (Print Publication: 2017).
Publication Year :: 2017
Abstract: There are limited therapeutic options to treat infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The lipoglycopeptide oritavancin exhibits in vitro activity against this pathogen, although its utility against infections caused by VREfm has not been clinically established. In this study, the pharmacodynamic activity of free-drug levels associated with 12 mg/kg/day of daptomycin and a single 1,200-mg dose of oritavancin were determined against three VanA VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model.<br /> (Copyright © 2017 American Society for Microbiology.)

Subjects :: Anti-Bacterial Agents pharmacokinetics
Daptomycin pharmacokinetics
Daptomycin pharmacology
Enterococcus faecium isolation & purification
Humans
Lipoglycopeptides
Microbial Sensitivity Tests
Vancomycin Resistance physiology
Vancomycin-Resistant Enterococci isolation & purification
Anti-Bacterial Agents pharmacology
Enterococcus faecium drug effects
Glycopeptides pharmacokinetics
Glycopeptides pharmacology
Gram-Positive Bacterial Infections drug therapy
Vancomycin-Resistant Enterococci drug effects

Full Text Access

Tools